APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaginitis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vaginitis Drug Market Outlook and Growth Opportunities 2026

20 December 2025218 pages

Choose your research edition.

Industry ResearchVaginitis Drug Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaginitis Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Vaginitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaginitis Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaginitis Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Vaginitis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vaginitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaginitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaginitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vaginitis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vaginitis Drug market include Bausch Health, Dare Bioscience, Galderma, Globela Pharma, Lupin Pharmaceuticals, Padagis, Perrigo, Prestige Consumer Healthcare and Sandoz, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Vaginitis Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaginitis Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaginitis Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Vaginitis Drug market.

Vaginitis Drug Segment by Company

Bausch Health

Dare Bioscience

Galderma

Globela Pharma

Lupin Pharmaceuticals

Padagis

Perrigo

Prestige Consumer Healthcare

Sandoz

Bayer

Sinopharm Group

HCPC

CR-Double Crane Pharmaceuticals

Pfizer

Conba

Kelun Pharmaceuticals

Livzon Pharmaceuticals

Lukang Pharmaceuticals

Luoxin Pharmaceuticals

Johnson & Johnson

Sanofi

Shandong Shijiazhuang Pharmaceutical Group

Teva Pharmaceuticals

Tongfang Pharmaceuticals

Wuhan Haite Biopharmaceuticals

Yuanda Pharmaceuticals

Yunnan Baiyao

Vaginitis Drug Segment by Type

External Drug

Oral Drug

Vaginitis Drug Segment by Application

Hospital Phamacy

Retail Phamacy

Online

Vaginitis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Vaginitis Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Vaginitis Drug key companies, revenue, market share, and recent developments.

3. To split the Vaginitis Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Vaginitis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vaginitis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Vaginitis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaginitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaginitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaginitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaginitis Drug industry.

Chapter 3: Detailed analysis of Vaginitis Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Vaginitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Vaginitis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vaginitis Drug Industry Trends Table 2. Vaginitis Drug Industry Drivers Table 3. Vaginitis Drug Industry Opportunities and Challenges Table 4. Vaginitis Drug Industry Restraints Table 5. Global Vaginitis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vaginitis Drug Revenue Share by Company (2021-2026) Table 7. Global Vaginitis Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Vaginitis Drug Key Company Manufacturing Base & Headquarters Table 9. Global Vaginitis Drug Company, Product Type & Application Table 10. Global Vaginitis Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Vaginitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of External Drug Table 15. Significant Companies of Oral Drug Table 16. Global Vaginitis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Vaginitis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Vaginitis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Vaginitis Drug Sales Value Share by Type (2021-2026) Table 20. Global Vaginitis Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Phamacy Table 22. Significant Companies of Retail Phamacy Table 23. Significant Companies of Online Table 24. Global Vaginitis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Vaginitis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Vaginitis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Vaginitis Drug Sales Value Share by Application (2021-2026) Table 28. Global Vaginitis Drug Sales Value Share by Application (2027-2032) Table 29. Global Vaginitis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Vaginitis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Vaginitis Drug Sales Value Share by Region (2021-2026) Table 32. Global Vaginitis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Vaginitis Drug Sales Value Share by Region (2027-2032) Table 34. Global Vaginitis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Vaginitis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Vaginitis Drug Sales Value Market Share by Country (2021-2026) Table 37. Global Vaginitis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Vaginitis Drug Sales Value Market Share by Country (2027-2032) Table 39. Bausch Health Company Information Table 40. Bausch Health Business Overview Table 41. Bausch Health Vaginitis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Bausch Health Vaginitis Drug Product Portfolio Table 43. Bausch Health Recent Development Table 44. Dare Bioscience Company Information Table 45. Dare Bioscience Business Overview Table 46. Dare Bioscience Vaginitis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Dare Bioscience Vaginitis Drug Product Portfolio Table 48. Dare Bioscience Recent Development Table 49. Galderma Company Information Table 50. Galderma Business Overview Table 51. Galderma Vaginitis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Galderma Vaginitis Drug Product Portfolio Table 53. Galderma Recent Development Table 54. Globela Pharma Company Information Table 55. Globela Pharma Business Overview Table 56. Globela Pharma Vaginitis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Globela Pharma Vaginitis Drug Product Portfolio Table 58. Globela Pharma Recent Development Table 59. Lupin Pharmaceuticals Company Information Table 60. Lupin Pharmaceuticals Business Overview Table 61. Lupin Pharmaceuticals Vaginitis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Lupin Pharmaceuticals Vaginitis Drug Product Portfolio Table 63. Lupin Pharmaceuticals Recent Development Table 64. Padagis Company Information Table 65. Padagis Business Overview Table 66. Padagis Vaginitis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Padagis Vaginitis Drug Product Portfolio Table 68. Padagis Recent Development Table 69. Perrigo Company Information Table 70. Perrigo Business Overview Table 71. Perrigo Vaginitis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Perrigo Vaginitis Drug Product Portfolio Table 73. Perrigo Recent Development Table 74. Prestige Consumer Healthcare Company Information Table 75. Prestige Consumer Healthcare Business Overview Table 76. Prestige Consumer Healthcare Vaginitis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Prestige Consumer Healthcare Vaginitis Drug Product Portfolio Table 78. Prestige Consumer Healthcare Recent Development Table 79. Sandoz Company Information Table 80. Sandoz Business Overview Table 81. Sandoz Vaginitis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Sandoz Vaginitis Drug Product Portfolio Table 83. Sandoz Recent Development Table 84. Bayer Company Information Table 85. Bayer Business Overview Table 86. Bayer Vaginitis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Bayer Vaginitis Drug Product Portfolio Table 88. Bayer Recent Development Table 89. Sinopharm Group Company Information Table 90. Sinopharm Group Business Overview Table 91. Sinopharm Group Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Sinopharm Group Vaginitis Drug Product Portfolio Table 93. Sinopharm Group Recent Development Table 94. HCPC Company Information Table 95. HCPC Business Overview Table 96. HCPC Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. HCPC Vaginitis Drug Product Portfolio Table 98. HCPC Recent Development Table 99. CR-Double Crane Pharmaceuticals Company Information Table 100. CR-Double Crane Pharmaceuticals Business Overview Table 101. CR-Double Crane Pharmaceuticals Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. CR-Double Crane Pharmaceuticals Vaginitis Drug Product Portfolio Table 103. CR-Double Crane Pharmaceuticals Recent Development Table 104. Pfizer Company Information Table 105. Pfizer Business Overview Table 106. Pfizer Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Pfizer Vaginitis Drug Product Portfolio Table 108. Pfizer Recent Development Table 109. Conba Company Information Table 110. Conba Business Overview Table 111. Conba Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Conba Vaginitis Drug Product Portfolio Table 113. Conba Recent Development Table 114. Kelun Pharmaceuticals Company Information Table 115. Kelun Pharmaceuticals Business Overview Table 116. Kelun Pharmaceuticals Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Kelun Pharmaceuticals Vaginitis Drug Product Portfolio Table 118. Kelun Pharmaceuticals Recent Development Table 119. Livzon Pharmaceuticals Company Information Table 120. Livzon Pharmaceuticals Business Overview Table 121. Livzon Pharmaceuticals Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Livzon Pharmaceuticals Vaginitis Drug Product Portfolio Table 123. Livzon Pharmaceuticals Recent Development Table 124. Lukang Pharmaceuticals Company Information Table 125. Lukang Pharmaceuticals Business Overview Table 126. Lukang Pharmaceuticals Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Lukang Pharmaceuticals Vaginitis Drug Product Portfolio Table 128. Lukang Pharmaceuticals Recent Development Table 129. Luoxin Pharmaceuticals Company Information Table 130. Luoxin Pharmaceuticals Business Overview Table 131. Luoxin Pharmaceuticals Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Luoxin Pharmaceuticals Vaginitis Drug Product Portfolio Table 133. Luoxin Pharmaceuticals Recent Development Table 134. Johnson & Johnson Company Information Table 135. Johnson & Johnson Business Overview Table 136. Johnson & Johnson Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Johnson & Johnson Vaginitis Drug Product Portfolio Table 138. Johnson & Johnson Recent Development Table 139. Sanofi Company Information Table 140. Sanofi Business Overview Table 141. Sanofi Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Sanofi Vaginitis Drug Product Portfolio Table 143. Sanofi Recent Development Table 144. Shandong Shijiazhuang Pharmaceutical Group Company Information Table 145. Shandong Shijiazhuang Pharmaceutical Group Business Overview Table 146. Shandong Shijiazhuang Pharmaceutical Group Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Shandong Shijiazhuang Pharmaceutical Group Vaginitis Drug Product Portfolio Table 148. Shandong Shijiazhuang Pharmaceutical Group Recent Development Table 149. Teva Pharmaceuticals Company Information Table 150. Teva Pharmaceuticals Business Overview Table 151. Teva Pharmaceuticals Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Teva Pharmaceuticals Vaginitis Drug Product Portfolio Table 153. Teva Pharmaceuticals Recent Development Table 154. Tongfang Pharmaceuticals Company Information Table 155. Tongfang Pharmaceuticals Business Overview Table 156. Tongfang Pharmaceuticals Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Tongfang Pharmaceuticals Vaginitis Drug Product Portfolio Table 158. Tongfang Pharmaceuticals Recent Development Table 159. Wuhan Haite Biopharmaceuticals Company Information Table 160. Wuhan Haite Biopharmaceuticals Business Overview Table 161. Wuhan Haite Biopharmaceuticals Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Wuhan Haite Biopharmaceuticals Vaginitis Drug Product Portfolio Table 163. Wuhan Haite Biopharmaceuticals Recent Development Table 164. Yuanda Pharmaceuticals Company Information Table 165. Yuanda Pharmaceuticals Business Overview Table 166. Yuanda Pharmaceuticals Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Yuanda Pharmaceuticals Vaginitis Drug Product Portfolio Table 168. Yuanda Pharmaceuticals Recent Development Table 169. Yunnan Baiyao Company Information Table 170. Yunnan Baiyao Business Overview Table 171. Yunnan Baiyao Vaginitis Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Yunnan Baiyao Vaginitis Drug Product Portfolio Table 173. Yunnan Baiyao Recent Development Table 174. Research Programs/Design for This Report Table 175. Authors List of This Report Table 176. Secondary Sources Table 177. Primary Sources List of Figures Figure 1. Vaginitis Drug Product Image Figure 2. Global Vaginitis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaginitis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaginitis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. External Drug Image Figure 8. Oral Drug Image Figure 9. Global Vaginitis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Vaginitis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Vaginitis Drug Sales Value Share by Type (2021-2032) Figure 12. Hospital Phamacy Image Figure 13. Retail Phamacy Image Figure 14. Online Image Figure 15. Global Vaginitis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Vaginitis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Vaginitis Drug Sales Value Share by Application (2021-2032) Figure 18. Global Vaginitis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Vaginitis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Vaginitis Drug Sales Value (2021-2032) & (US$ Million) Figure 21. North America Vaginitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Vaginitis Drug Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Vaginitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Vaginitis Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Vaginitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Vaginitis Drug Sales Value (2021-2032) & (US$ Million) Figure 27. South America Vaginitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Vaginitis Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Vaginitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Vaginitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Vaginitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Vaginitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • External Drug
  • Oral Drug
Applications
  • Hospital Phamacy
  • Retail Phamacy
  • Online
Companies covered
  • Bausch Health
  • Dare Bioscience
  • Galderma
  • Globela Pharma
  • Lupin Pharmaceuticals
  • Padagis
  • Perrigo
  • Prestige Consumer Healthcare
  • Sandoz
  • Bayer
  • Sinopharm Group
  • HCPC
  • CR-Double Crane Pharmaceuticals
  • Pfizer
  • Conba
  • Kelun Pharmaceuticals
  • Livzon Pharmaceuticals
  • Lukang Pharmaceuticals
  • Luoxin Pharmaceuticals
  • Johnson & Johnson
  • Sanofi
  • Shandong Shijiazhuang Pharmaceutical Group
  • Teva Pharmaceuticals
  • Tongfang Pharmaceuticals
  • Wuhan Haite Biopharmaceuticals
  • Yuanda Pharmaceuticals
  • Yunnan Baiyao

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vaginitis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vaginitis Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Vaginitis Drug Market Dynamics
  1. 2.1 Vaginitis Drug Industry Trends
  2. 2.2 Vaginitis Drug Industry Drivers
  3. 2.3 Vaginitis Drug Industry Opportunities and Challenges
  4. 2.4 Vaginitis Drug Industry Restraints
3 Vaginitis Drug Market by Company
  1. 3.1 Global Vaginitis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Vaginitis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Vaginitis Drug Company Ranking (2024-2026)
  4. 3.4 Global Vaginitis Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Vaginitis Drug Company Product Type and Application
  6. 3.6 Global Vaginitis Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Vaginitis Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Vaginitis Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Vaginitis Drug Market by Type
  1. 4.1 Vaginitis Drug Type Introduction
  2. 4.1.1 External Drug
  3. 4.1.2 Oral Drug
  4. 4.2 Global Vaginitis Drug Sales Value by Type
  5. 4.2.1 Global Vaginitis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vaginitis Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Vaginitis Drug Sales Value Share by Type (2021-2032)
5 Vaginitis Drug Market by Application
  1. 5.1 Vaginitis Drug Application Introduction
  2. 5.1.1 Hospital Phamacy
  3. 5.1.2 Retail Phamacy
  4. 5.1.3 Online
  5. 5.2 Global Vaginitis Drug Sales Value by Application
  6. 5.2.1 Global Vaginitis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vaginitis Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Vaginitis Drug Sales Value Share by Application (2021-2032)
6 Vaginitis Drug Regional Value Analysis
  1. 6.1 Global Vaginitis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaginitis Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Vaginitis Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Vaginitis Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vaginitis Drug Sales Value (2021-2032)
  7. 6.3.2 North America Vaginitis Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Vaginitis Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Vaginitis Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Vaginitis Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Vaginitis Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Vaginitis Drug Sales Value (2021-2032)
  16. 6.6.2 South America Vaginitis Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Vaginitis Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Vaginitis Drug Sales Value Share by Country, 2025 VS 2032
7 Vaginitis Drug Country-level Value Analysis
  1. 7.1 Global Vaginitis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vaginitis Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Vaginitis Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Vaginitis Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Vaginitis Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Vaginitis Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Vaginitis Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Vaginitis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Vaginitis Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Vaginitis Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Vaginitis Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Vaginitis Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Vaginitis Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Vaginitis Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Vaginitis Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Vaginitis Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Vaginitis Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Vaginitis Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Vaginitis Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Vaginitis Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Vaginitis Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Vaginitis Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Vaginitis Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Vaginitis Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Vaginitis Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Vaginitis Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Vaginitis Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Vaginitis Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Vaginitis Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Vaginitis Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Vaginitis Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Vaginitis Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Vaginitis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Vaginitis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bausch Health
  2. 8.1.1 Bausch Health Company Information
  3. 8.1.2 Bausch Health Business Overview
  4. 8.1.3 Bausch Health Vaginitis Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bausch Health Vaginitis Drug Product Portfolio
  6. 8.1.5 Bausch Health Recent Developments
  7. 8.2 Dare Bioscience
  8. 8.2.1 Dare Bioscience Company Information
  9. 8.2.2 Dare Bioscience Business Overview
  10. 8.2.3 Dare Bioscience Vaginitis Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Dare Bioscience Vaginitis Drug Product Portfolio
  12. 8.2.5 Dare Bioscience Recent Developments
  13. 8.3 Galderma
  14. 8.3.1 Galderma Company Information
  15. 8.3.2 Galderma Business Overview
  16. 8.3.3 Galderma Vaginitis Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Galderma Vaginitis Drug Product Portfolio
  18. 8.3.5 Galderma Recent Developments
  19. 8.4 Globela Pharma
  20. 8.4.1 Globela Pharma Company Information
  21. 8.4.2 Globela Pharma Business Overview
  22. 8.4.3 Globela Pharma Vaginitis Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Globela Pharma Vaginitis Drug Product Portfolio
  24. 8.4.5 Globela Pharma Recent Developments
  25. 8.5 Lupin Pharmaceuticals
  26. 8.5.1 Lupin Pharmaceuticals Company Information
  27. 8.5.2 Lupin Pharmaceuticals Business Overview
  28. 8.5.3 Lupin Pharmaceuticals Vaginitis Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lupin Pharmaceuticals Vaginitis Drug Product Portfolio
  30. 8.5.5 Lupin Pharmaceuticals Recent Developments
  31. 8.6 Padagis
  32. 8.6.1 Padagis Company Information
  33. 8.6.2 Padagis Business Overview
  34. 8.6.3 Padagis Vaginitis Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Padagis Vaginitis Drug Product Portfolio
  36. 8.6.5 Padagis Recent Developments
  37. 8.7 Perrigo
  38. 8.7.1 Perrigo Company Information
  39. 8.7.2 Perrigo Business Overview
  40. 8.7.3 Perrigo Vaginitis Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Perrigo Vaginitis Drug Product Portfolio
  42. 8.7.5 Perrigo Recent Developments
  43. 8.8 Prestige Consumer Healthcare
  44. 8.8.1 Prestige Consumer Healthcare Company Information
  45. 8.8.2 Prestige Consumer Healthcare Business Overview
  46. 8.8.3 Prestige Consumer Healthcare Vaginitis Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Prestige Consumer Healthcare Vaginitis Drug Product Portfolio
  48. 8.8.5 Prestige Consumer Healthcare Recent Developments
  49. 8.9 Sandoz
  50. 8.9.1 Sandoz Company Information
  51. 8.9.2 Sandoz Business Overview
  52. 8.9.3 Sandoz Vaginitis Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sandoz Vaginitis Drug Product Portfolio
  54. 8.9.5 Sandoz Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer Vaginitis Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bayer Vaginitis Drug Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Sinopharm Group
  62. 8.11.1 Sinopharm Group Company Information
  63. 8.11.2 Sinopharm Group Business Overview
  64. 8.11.3 Sinopharm Group Vaginitis Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sinopharm Group Vaginitis Drug Product Portfolio
  66. 8.11.5 Sinopharm Group Recent Developments
  67. 8.12 HCPC
  68. 8.12.1 HCPC Company Information
  69. 8.12.2 HCPC Business Overview
  70. 8.12.3 HCPC Vaginitis Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 HCPC Vaginitis Drug Product Portfolio
  72. 8.12.5 HCPC Recent Developments
  73. 8.13 CR-Double Crane Pharmaceuticals
  74. 8.13.1 CR-Double Crane Pharmaceuticals Company Information
  75. 8.13.2 CR-Double Crane Pharmaceuticals Business Overview
  76. 8.13.3 CR-Double Crane Pharmaceuticals Vaginitis Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CR-Double Crane Pharmaceuticals Vaginitis Drug Product Portfolio
  78. 8.13.5 CR-Double Crane Pharmaceuticals Recent Developments
  79. 8.14 Pfizer
  80. 8.14.1 Pfizer Company Information
  81. 8.14.2 Pfizer Business Overview
  82. 8.14.3 Pfizer Vaginitis Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Pfizer Vaginitis Drug Product Portfolio
  84. 8.14.5 Pfizer Recent Developments
  85. 8.15 Conba
  86. 8.15.1 Conba Company Information
  87. 8.15.2 Conba Business Overview
  88. 8.15.3 Conba Vaginitis Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Conba Vaginitis Drug Product Portfolio
  90. 8.15.5 Conba Recent Developments
  91. 8.16 Kelun Pharmaceuticals
  92. 8.16.1 Kelun Pharmaceuticals Company Information
  93. 8.16.2 Kelun Pharmaceuticals Business Overview
  94. 8.16.3 Kelun Pharmaceuticals Vaginitis Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Kelun Pharmaceuticals Vaginitis Drug Product Portfolio
  96. 8.16.5 Kelun Pharmaceuticals Recent Developments
  97. 8.17 Livzon Pharmaceuticals
  98. 8.17.1 Livzon Pharmaceuticals Company Information
  99. 8.17.2 Livzon Pharmaceuticals Business Overview
  100. 8.17.3 Livzon Pharmaceuticals Vaginitis Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Livzon Pharmaceuticals Vaginitis Drug Product Portfolio
  102. 8.17.5 Livzon Pharmaceuticals Recent Developments
  103. 8.18 Lukang Pharmaceuticals
  104. 8.18.1 Lukang Pharmaceuticals Company Information
  105. 8.18.2 Lukang Pharmaceuticals Business Overview
  106. 8.18.3 Lukang Pharmaceuticals Vaginitis Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Lukang Pharmaceuticals Vaginitis Drug Product Portfolio
  108. 8.18.5 Lukang Pharmaceuticals Recent Developments
  109. 8.19 Luoxin Pharmaceuticals
  110. 8.19.1 Luoxin Pharmaceuticals Company Information
  111. 8.19.2 Luoxin Pharmaceuticals Business Overview
  112. 8.19.3 Luoxin Pharmaceuticals Vaginitis Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Luoxin Pharmaceuticals Vaginitis Drug Product Portfolio
  114. 8.19.5 Luoxin Pharmaceuticals Recent Developments
  115. 8.20 Johnson & Johnson
  116. 8.20.1 Johnson & Johnson Company Information
  117. 8.20.2 Johnson & Johnson Business Overview
  118. 8.20.3 Johnson & Johnson Vaginitis Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Johnson & Johnson Vaginitis Drug Product Portfolio
  120. 8.20.5 Johnson & Johnson Recent Developments
  121. 8.21 Sanofi
  122. 8.21.1 Sanofi Company Information
  123. 8.21.2 Sanofi Business Overview
  124. 8.21.3 Sanofi Vaginitis Drug Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Sanofi Vaginitis Drug Product Portfolio
  126. 8.21.5 Sanofi Recent Developments
  127. 8.22 Shandong Shijiazhuang Pharmaceutical Group
  128. 8.22.1 Shandong Shijiazhuang Pharmaceutical Group Company Information
  129. 8.22.2 Shandong Shijiazhuang Pharmaceutical Group Business Overview
  130. 8.22.3 Shandong Shijiazhuang Pharmaceutical Group Vaginitis Drug Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Shandong Shijiazhuang Pharmaceutical Group Vaginitis Drug Product Portfolio
  132. 8.22.5 Shandong Shijiazhuang Pharmaceutical Group Recent Developments
  133. 8.23 Teva Pharmaceuticals
  134. 8.23.1 Teva Pharmaceuticals Company Information
  135. 8.23.2 Teva Pharmaceuticals Business Overview
  136. 8.23.3 Teva Pharmaceuticals Vaginitis Drug Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Teva Pharmaceuticals Vaginitis Drug Product Portfolio
  138. 8.23.5 Teva Pharmaceuticals Recent Developments
  139. 8.24 Tongfang Pharmaceuticals
  140. 8.24.1 Tongfang Pharmaceuticals Company Information
  141. 8.24.2 Tongfang Pharmaceuticals Business Overview
  142. 8.24.3 Tongfang Pharmaceuticals Vaginitis Drug Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Tongfang Pharmaceuticals Vaginitis Drug Product Portfolio
  144. 8.24.5 Tongfang Pharmaceuticals Recent Developments
  145. 8.25 Wuhan Haite Biopharmaceuticals
  146. 8.25.1 Wuhan Haite Biopharmaceuticals Company Information
  147. 8.25.2 Wuhan Haite Biopharmaceuticals Business Overview
  148. 8.25.3 Wuhan Haite Biopharmaceuticals Vaginitis Drug Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Wuhan Haite Biopharmaceuticals Vaginitis Drug Product Portfolio
  150. 8.25.5 Wuhan Haite Biopharmaceuticals Recent Developments
  151. 8.26 Yuanda Pharmaceuticals
  152. 8.26.1 Yuanda Pharmaceuticals Company Information
  153. 8.26.2 Yuanda Pharmaceuticals Business Overview
  154. 8.26.3 Yuanda Pharmaceuticals Vaginitis Drug Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Yuanda Pharmaceuticals Vaginitis Drug Product Portfolio
  156. 8.26.5 Yuanda Pharmaceuticals Recent Developments
  157. 8.27 Yunnan Baiyao
  158. 8.27.1 Yunnan Baiyao Company Information
  159. 8.27.2 Yunnan Baiyao Business Overview
  160. 8.27.3 Yunnan Baiyao Vaginitis Drug Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Yunnan Baiyao Vaginitis Drug Product Portfolio
  162. 8.27.5 Yunnan Baiyao Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst